The following is a detailed excerpt of an interview conducted over email with the CEO of Brainstorm Cell Therapeutics, Chaim Lebovits.
This interview follows from an article we wrote about BCLI in May.
The interview discusses critical aspects of BCLI, including the phase 2 trial data, ongoing phase 3 data, as well as funding.
This level of disease stabilization has not been observed to this date in approved or investigational ALS therapies.
- Mr. Chaim Lebovits, CEO, Brainstorm Cell Therapeutics
In May of this year, I published an article